Ornithine

證據等級: L5

預測適應症: 10 個

Ornithine: From Unknown Original Indication to Congenital Prothrombin Deficiency

One-Sentence Summary

Ornithine (DrugBank ID DB00129) is an endogenous amino acid; this evidence pack contains no record of an approved original indication or mechanism of action for it. The TxGNN model predicts potential relevance to Congenital Prothrombin Deficiency, but this is currently supported by only 1 loosely related clinical trial and 0 publications, with no identified mechanistic connection between the two.

Quick Overview

Item	Content
Original Indication	Not on record (no approved indication data available)
Predicted New Indication	Congenital Prothrombin Deficiency
TxGNN Prediction Score	97.52%
Evidence Level	L5
South Africa Market Status	Not Marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism-of-action data for Ornithine is not available in this evidence pack (data gap DG002, High severity), and no approved original indication is on file. Based on general pharmacology, ornithine is an endogenous amino acid that functions primarily in the urea cycle (ammonia detoxification) and as a precursor for polyamine biosynthesis via ornithine decarboxylase.

Congenital Prothrombin Deficiency is a rare, inherited coagulation factor (Factor II) deficiency. There is no known biochemical or pharmacological pathway linking ornithine metabolism to coagulation factor synthesis. The underlying scoring rationale for this candidate explicitly states that no mechanistic link was identified, and that the one supporting clinical trial co-occurs with this indication only because both are registered as rare inherited metabolic/genetic disorders — not because of any real disease-mechanism overlap.

Given the absence of a plausible mechanism and a weak, off-topic evidence base, this prediction should be treated as a low-confidence, model-only signal rather than a clinically actionable hypothesis at this time.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04612764	N/A	Recruiting	62	Multi-center cross-sectional study of non-invasive biomarkers (Fibroscan, MRE, serum) for liver fibrosis in urea cycle disorders — not a study of congenital prothrombin deficiency; relevance graded C (topic mismatch)

Literature Evidence

Currently no related literature available.

South Africa Market Information

Ornithine is currently not marketed in South Africa — this evidence pack records 0 SAHPRA registrations, so no product/dosage-form details are available.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence level is L5 (model prediction only) — no mechanistic link connects ornithine metabolism to prothrombin/coagulation factor deficiency, and the sole associated clinical trial addresses an unrelated topic (urea cycle disorder liver fibrosis biomarkers, not prothrombin deficiency).

To proceed, the following is needed:

TFDA/SAHPRA-approved Professional Information, including warnings and contraindications (currently a Blocking data gap, DG001)
Detailed mechanism of action data for ornithine (High-severity data gap, DG002)
Disease-specific clinical trials or literature directly evaluating ornithine (or a related agent) in congenital prothrombin deficiency or coagulation disorders
Confirmation of ornithine’s original approved indication, to establish a baseline for the repurposing rationale
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.